Eleven Biotherapeutics Completes Exclusive Licensing Deal for IL-6 Antagonist Antibody Technology, Including EBI-031

by Business Wire • 2016/08/16 • 0 Comments

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven has granted Roche an exclusive, worldwide license to develop and commercialize EBI-031 and all other IL-6 antagonist antibody technology owned by Eleven.

← Resumen: Oculis completa ronda de financiación de serie A

Oculis Completes Series A Financing →

Post navigation